Fusion Pharmaceuticals

Fusion Pharmaceuticals in its US$105 million Series B financing


Fusion Pharmaceuticals Inc.


US$105 million


Emerging and High Growth Companies

Date Closed

April 2019


Venture Capital

Lead Office


On April 2, 2019, Fusion Pharmaceuticals announced a US$105 million Series B financing led by health investor, OrbiMed Advisors and medical-technology company Varian Medical Systems.  The proceeds will allow Fusion Pharmaceuticals to expand its team and build out the clinical program in targeted alpha therapeutics, and accelerate a pipeline of new radiopharmaceuticals and combination therapy strategies.

Fusion Pharmaceuticals is a biopharmaceutical company that develops targeted alpha-particle radiotherapeutics for the treatment of chemotherapy resistant cancers.

Osler, Hoskin & Harcourt LLP represented Fusion Pharmaceuticals with a team led by Chad Bayne that included Michael Grantmyre, Sahil Chopra (Emerging and High Growth Companies), Paul Seraganian, Chad West (Tax), and Peter Glossop (Competition & Antitrust).

Chad Bayne
Key Contact

Chad Bayne

Partner, Emerging and High Growth Companies

Michael Grantmyre

Michael Grantmyre

Senior Associate, Emerging and High Growth Companies

Sahil Chopra

Sahil Chopra

Associate, Corporate

Paul Seraganian - Cross Border Tax Lawyer

Paul Seraganian

New York Managing Partner

Peter Glossop - Foreign Investment Lawyer

Peter Glossop

Partner, Competition/Antitrust & Foreign Investment